BioXcel Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $182 | $206 | $256 | $98 |
Gross Profit | 160 | -135 | 224 | 87 |
EBITDA | -10,438 | -8,435 | -8,075 | -26,463 |
EBIT | -10,456 | -8,493 | -8,149 | -26,538 |
Net Income | -14,713 | -12,691 | -12,545 | -30,911 |
Net Change In Cash | 182 | 206 | 256 | 98 |
Free Cash Flow | -6,098 | -11,809 | -14,210 | -18,787 |
Cash | 12,841 | 17,180 | 28,415 | 37,320 |
Basic Shares | 12,208 | 12,208 | 12,208 | 14,196 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $642 | $2,266 | $1,380 | $375 |
Gross Profit | 478 | 123 | 120 | 355 |
EBITDA | -52,613 | -44,161 | -165,421 | -157,217 |
EBIT | -52,913 | -44,470 | -165,739 | -157,544 |
Net Income | -69,897 | -59,599 | -179,053 | -165,757 |
Net Change In Cash | 642 | 2,266 | 1,380 | 375 |
Cost of Revenue | -39,243 | |||
Free Cash Flow | -57,615 | -72,027 | -155,026 | -135,480 |
Cash | 28,415 | 29,854 | 65,221 | 193,725 |
Basic Shares | 12,208 | 2,535 | 1,820 | 1,750 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.49 |
2026-03-31 | -$0.54 |
2025-12-31 | -$1.02 |
2025-09-30 | -$2.16 |